SCRI Oncology Partners ( Site 7000)

Nashville, Tennessee 37203

8 studies enrolling now · 8 studies all time

What they study most

Advanced Gastrointestinal Stromal Tumor, Breast Cancer, Breast Neoplasms, Follicular Lymphoma, HIF-2α Mutated Cancers, Malignant Neoplasms, Pancreatic Neuroendocrine Tumor, Pheochromocytoma/Paraganglioma, Prostate Cancer Metastatic, Small Cell Lung Cancer Extensive Stage, Triple-Negative Breast Cancer, Von Hippel-Lindau Disease

Studies at this site

• Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) — Recruiting now
• Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) — Recruiting now
• A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007) — Recruiting now
• A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) — Recruiting now
• Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015) — Recruiting now
• A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003) — Recruiting now
• Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) — Recruiting now
• Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) — Recruiting now